Great discussion by Dr. Rebecca Heist (@MassGeneralBrigham) at #ESMO2026 summarizing key Phase III trials targeting acquired resistance in EGFRm NSCLC! 馃К
Key takeaways on EGFR + MET TKI strategies:
鈻笍 SAFFRON (Osi + Savo vs Chemo): PFS 7.6 vs 5.4 mo (HR 0.55), OS 17.8 vs 12.9 mo (HR 0.68) post-3rd gen TKI.
鈻笍 SACHI (Osi + Savo): PFS 8.2 vs 4.5 mo (HR 0.34) | ORR 63% vs 36%.
鈻笍 MARIPOSA-2 Benchmarking: Ami-chemo gives PFS 8.3 vs 4.2 mo (HR 0.44), but without MET selection.
Dr. Heist highlighted critical open questions: defining optimal MET cutoffs, balancing oral vs IV regimens, and distinct AE profiles across combinations!聽
#LungCancer #OncoX #ESMO26 #NSCLC
14 views 路 1 like 路 0 reposts 路 0 replies
Source: Young Kwang Chae, MD, MPH, MBA 路 x.com